Skip to main content
editorial
. 2018 Dec 11;21(2):143–145. doi: 10.1093/neuonc/noy188

Fig. 1.

Fig. 1

Pediatric low-grade gliomas exhibit frequent genetic alterations that activate the mitogen-activated protein kinase pathway (depicted). Small-molecule inhibitors that have been trialed (or are currently being trialed) in early-phase pediatric clinical trials are shown. The combination of carboplatin and everolimus (shown in red) makes use of distinct mechanisms of action.